PSMA靶向PET/CT能否成为评估肺癌患者脑转移存在与否的有价值工具:一例病例报告
一名78岁男性同步诊断前列腺癌与肺腺癌,为前列腺癌分期行[18F]F-PSMA 1007 PET/CT,除已知右肺病灶外,脑内左额叶与颞叶显示2处异常摄取,后续MRI证实PET/CT所见病灶。作者指出PSMA靶向放射性药物不在健康脑实质中聚集,近期文献报告PSMA靶向PET/CT在胶质瘤及非前列腺癌转移瘤中有前景,该应用有待进一步探索。
要点
- 78岁男性同步诊断前列腺癌与肺腺癌,行[18F]F-PSMA 1007 PET/CT分期。
- PSMA靶向PET/CT显示脑内左额叶与颞叶2处异常摄取,后续MRI证实。
- PSMA放射性药物不在健康脑实质聚集,该应用有待进一步探索。
核心结论
- PSMA靶向放射性药物不在健康脑实质中聚集,近期文献报告PSMA靶向PET/CT在胶质瘤及非前列腺癌转移瘤中有前景,该应用有待进一步探索。
研究设计与样本
- 病例报告:一名78岁男性同步诊断前列腺癌与肺腺癌,为前列腺癌分期行[18F]F-PSMA 1007 PET/CT。
主要发现
- 除先前已知的右肺病灶外,PSMA靶向PET/CT显示脑内左额叶与颞叶2处异常摄取。
- 后续MRI证实了PET/CT所观察到的病灶。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出该应用有待进一步探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 78-year-old man with synchronous diagnosis of prostate cancer and lung adenocarcinoma was referred to our institute for prostate cancer staging with [ 18 F]F-prostate-specific membrane antigen (PSMA) 1007 PET/CT. In addition to the previously known lesion of the right lung, PSMA-targeted PET/CT highlighted 2 areas of abnormal uptake in the brain, in the left frontal and temporal lobes. A subsequent MRI confirmed the lesions observed on PET/CT. Because PSMA-targeting radiopharmaceuticals do not accumulate in healthy brain parenchyma, and recent literature reported promising performances of PSMA-targeted PET/CT in gliomas and metastases from tumors other than prostate cancer, this employment of PSMA radioligands needs to be further explored.
引用
- Dall'Armellina S, Cauda S, Duca S, et al. Can PSMA-Targeting PET/CT Be a Valuable Instrument to Assess the Presence of Brain Metastases in Lung Cancer Patients?: A Case Report. Clin Nucl Med. 2023. PMID: 37083740. doi:10.1097/RLU.0000000000004675
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。